HCG Monotherapy as a TRT Alternative — What the Research Actually Shows for UK Men

HCG monotherapy as a TRT alternative is one of the most searched and least understood topics in UK mens health and bodybuilding crossover spaces. The question is straightforward. If HCG stimulates the testes to produce testosterone by mimicking LH, can it replace exogenous testosterone entirely for men who want to raise their testosterone levels without shutting down their HPG axis, losing testicular function, or becoming infertile? The clinical answer is yes, with specific caveats that determine who it works for and who it does not.

Why some men want an alternative to standard TRT

Standard testosterone replacement therapy is effective at raising serum testosterone. It is less effective at everything else that matters to men who want to optimise their health without giving up their fertility or their testicular function.

Exogenous testosterone suppresses the HPG axis almost universally. LH and FSH fall to undetectable levels within weeks. The testes stop producing testosterone and sperm. Testicular atrophy follows. Azoospermia develops in up to 60% of men within six months of continuous TRT according to American Urological Association guidelines. For men in their twenties and thirties who want to preserve fertility or simply want to avoid the cascade of hormonal suppression that comes with injecting testosterone, standard TRT carries a significant functional cost.

There is also the haematocrit concern. Exogenous testosterone stimulates erythropoiesis. Haematocrit rises. Blood viscosity increases. Cardiovascular risk increases with it. A 2022 study published in Cureus via NIH PMC found that HCG monotherapy led to an advantageous decrease in haematocrit compared to testosterone therapy, suggesting it may carry a lower cardiovascular risk profile from this specific mechanism.

What HCG monotherapy actually does

HCG binds the LH/CG receptor on Leydig cells directly. It stimulates intratesticular testosterone production through the same signalling pathway that endogenous LH uses, but with a longer half-life of 24 to 36 hours compared to endogenous LH’s 20 minutes. The result is sustained Leydig cell stimulation and elevated testosterone production from within the testes rather than from an injected source.

Crucially, this approach does not suppress the HPG axis the way exogenous testosterone does. The testes are being stimulated rather than bypassed. The HPG axis remains intact. LH and FSH from the pituitary continue to function. The testes maintain their volume and spermatogenic function because they are still receiving stimulation. This is the fundamental pharmacological difference that makes HCG monotherapy attractive for men who cannot or will not accept the fertility and testicular suppression of standard TRT.

A multi-institutional retrospective study published in the Journal of Urology via NIH PMC evaluated HCG monotherapy in men with symptoms of hypogonadism but testosterone levels above 300 ng/dL, who did not qualify for or want standard TRT. The study found that HCG monotherapy produced statistically significant increases in serum testosterone and was well tolerated as a standalone treatment.

What the clinical evidence shows

The evidence base for HCG monotherapy is growing but still smaller than the literature on standard testosterone therapy. The most relevant studies for the UK bodybuilding and mens health audience cover three distinct use cases.

HCG monotherapy for men who have previously used anabolic steroids

The Cureus study published in 2022 specifically examined HCG monotherapy in men with a history of exogenous testosterone use. This is the most relevant population for UK bodybuilding readers. The study found a statistically significant increase in mean testosterone levels in men who had their baseline labs completed outside their previous testosterone therapy window, rising from 307 ng/dL to 422 ng/dL on HCG monotherapy. PSA levels decreased significantly, and haematocrit trended lower than expected with standard testosterone therapy. The authors concluded that HCG is a safe and effective alternative to traditional testosterone therapy for men with a history of exogenous testosterone use.

HCG monotherapy for fertility preservation during testosterone therapy

Research published in Fertility and Sterility by Hsieh et al. evaluated 500IU HCG every other day in men on testosterone replacement who wished to preserve fertility. Mean sperm density and motility were maintained at pre-TRT levels during the combined protocol. The authors concluded that low-dose HCG is protective of spermatogenesis when given concurrently with testosterone therapy.

This is not pure monotherapy but demonstrates the same principle. The intratesticular testosterone maintained by HCG is sufficient to sustain spermatogenesis even when the HPG axis is suppressed by exogenous testosterone. When HCG is used as the sole testosterone-raising intervention, the HPG axis is not suppressed at all, and spermatogenesis is preserved even more completely.

HCG monotherapy for symptomatic hypogonadism in men not qualifying for standard TRT

A 2024 narrative review published in Medicina via MDPI summarised the literature on HCG as an alternative to TRT for hypogonadal patients, noting that for patients seeking to conceive and responding to HCG or clomiphene, these drugs may be a better option than testosterone. The review noted a lack of long-term studies beyond three years as the primary evidence gap, but acknowledged that short and medium-term data supports HCG monotherapy as a viable approach for secondary hypogonadism.

Who HCG monotherapy works for and who it does not

HCG monotherapy works through the Leydig cells. This means it only works if the Leydig cells are capable of responding to stimulation. If the primary deficit is at the testicular level, HCG will produce a limited response.

The men most likely to benefit from HCG monotherapy fall into two categories. The first is men with secondary hypogonadism, meaning the pituitary is not producing adequate LH rather than the testes being incapable of responding. Secondary hypogonadism is the most common form in younger men and in men who have suppressed their HPG axis through steroid use. In this case, the testes are capable of producing testosterone if they receive the LH signal that HCG provides. The second category is men who want to raise testosterone to optimise wellbeing and performance without accepting the fertility and testicular suppression of standard TRT.

HCG monotherapy is less suitable for men with primary hypogonadism, where the testes themselves are the source of the deficiency. In primary hypogonadism, LH is already elevated because the pituitary is trying to stimulate testes that are not responding. Adding HCG in this scenario adds more stimulation to tissue that is already failing to respond to maximum endogenous stimulation. The outcome is predictably limited.

It is also limited in the context of post-steroid recovery where Leydig cell population has been significantly reduced by years of suppressive use. Research published in Fertility and Sterility from Baylor College of Medicine in 2024 found that HCG combined with FSH produced superior outcomes for spermatogenesis restoration in men recovering from androgen-induced azoospermia compared to HCG alone, suggesting that the FSH component is necessary when Sertoli cell function has also been impaired by prolonged suppression.

Practical protocol for HCG monotherapy

The doses used in clinical studies for monotherapy range from 1000 to 3000IU injected subcutaneously two to three times per week. Lower doses in the 500 to 1000IU range are used for maintenance and fertility preservation during concurrent testosterone use. The higher monotherapy doses are used to achieve testosterone levels in the normal to high-normal range as a standalone intervention.

The practical approach for a UK man considering HCG monotherapy as an alternative to standard TRT is to start at 1000IU three times per week and assess testosterone response at six to eight weeks with a full hormone panel including total testosterone, free testosterone, LH, FSH, oestradiol and haematocrit. HCG stimulates testosterone which aromatises to oestradiol. Monitoring oestradiol and managing it with a low-dose aromatase inhibitor if symptoms appear is appropriate. Haematocrit should be checked at baseline and at eight weeks.

Intex Pharma HCG 5000IU provides pharmaceutical grade HCG at £37.00 per vial. A standard monotherapy protocol at 1000IU three times weekly uses approximately 3000IU per week, meaning a single 5000IU vial reconstituted at 2500IU per ml provides approximately 1.5 weeks of treatment. Planning supply accordingly before starting is practical.

HCG monotherapy versus Clomid or Nolvadex for raising testosterone

HCG, Clomid and Nolvadex all raise endogenous testosterone but through different mechanisms. it works directly at the testicular level. Clomid and Nolvadex work at the hypothalamic and pituitary level by blocking oestrogen receptors and increasing GnRH, LH and FSH output.

For men who have suppressed HPG axes from steroid use, the distinction matters. SERMs depend on the pituitary responding to reduced oestrogen feedback by increasing LH and FSH. If the hypothalamic-pituitary component of the axis is slow to recover, SERM response is limited. HCG bypasses this entirely and acts directly on the testes. This is why the recommended PCT sequence is HCG first to restore testicular responsiveness, then SERMs to restore autonomous HPG axis function rather than the two simultaneously.

For long-term monotherapy as a TRT alternative, the SERM approach has less evidence than HCG and carries the zuclomiphene accumulation issue with Clomid on extended use. A review published in the International Journal of Molecular Sciences via NIH PMC noted that while clomiphene and tamoxifen show increases in testosterone in studies, the data supporting their efficacy on hypogonadal symptoms specifically is insufficient for clear clinical recommendations, and their use remains off-label for this purpose.

Available now at Intex Pharma UK

Intex Pharma HCG 5000IU — in stock at £37.00, same day despatch

Pharmaceutical grade Human Chorionic Gonadotropin. Used for TRT alternative protocols, fertility preservation and PCT support. Same day UK despatch. Ships worldwide. 15% off with Bitcoin using code INTEXBTC15.

Buy Intex Pharma HCG 5000IU — £37.00 Read verified reviews

Frequently asked questions

Can HCG replace testosterone replacement therapy completely?

For men with secondary hypogonadism where the testes are capable of responding to LH stimulation, HCG monotherapy can raise testosterone to normal or near-normal levels without exogenous testosterone. The 2022 Cureus study found statistically significant testosterone increases in men with a history of androgen use who switched to HCG monotherapy. It is not suitable for men with primary hypogonadism where the testes themselves are the source of the deficiency and are already failing to respond to maximal endogenous LH stimulation.

Does HCG monotherapy preserve fertility?

Yes. Unlike exogenous testosterone, HCG does not suppress the HPG axis. The testes continue receiving stimulation and spermatogenesis is maintained. Research by Hsieh et al. in Fertility and Sterility demonstrated that 500IU HCG every other day preserved spermatogenesis in men on TRT. When HCG is used as a standalone intervention without exogenous testosterone, HPG axis suppression does not occur and fertility preservation is even more complete.

How much does HCG raise testosterone?

The response varies by individual, dose and the functional capacity of the Leydig cells. The Cureus 2022 study found testosterone rising from a mean of 307 ng/dL to 422 ng/dL on HCG monotherapy. Clinical protocols using 1000 to 3000IU three times weekly typically aim for testosterone in the 400 to 700 ng/dL range, which covers the normal to high-normal therapeutic window without requiring supraphysiological levels.

Does HCG monotherapy cause the same side effects as TRT?

Not all of them. HCG does not cause testicular atrophy or suppress spermatogenesis. It causes lower haematocrit elevation than exogenous testosterone, reducing one of TRT’s primary cardiovascular risks. hcg does stimulate testosterone production which aromatises to oestradiol, so oestrogen management with a low-dose aromatase inhibitor may be needed. It also carries a smaller risk of Leydig cell desensitisation at high doses over extended periods, which is managed by keeping doses at the minimum effective level.

Can I use HCG monotherapy after years of steroid use?

Yes, but the response depends on the functional capacity of the Leydig cell population. Men who have run multiple heavily suppressive cycles over many years may have reduced Leydig cell populations that limit the maximum testosterone output achievable with HCG stimulation. A trial of HCG monotherapy with bloodwork at six to eight weeks is the practical way to assess individual response and determine whether monotherapy achieves adequate testosterone levels or whether standard TRT is necessary.

What bloodwork should I run on HCG monotherapy?

At baseline and again at six to eight weeks, run total testosterone, free testosterone, LH, FSH, oestradiol, haematocrit and PSA. The expected pattern on successful HCG monotherapy is rising testosterone with LH and FSH remaining within range rather than suppressing, and oestradiol rising in proportion to the increased testosterone. Rising haematocrit without the elevation seen on standard TRT is the expected cardiovascular profile. PSA should be monitored as HCG stimulates testicular and potentially prostatic androgen activity.